First results of two multi-center international Phase 1 dose-escalation and -expansion clinical trials of novel T-cell bispecific antibody cibisatamab as…
immunotherapy
Published in The Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint…
The kick-off meeting of PragmaTIL, a project that will finance a pioneering academic clinical trial in advanced therapies, coordinated by…
Reported today at the ESMO Congress 2023 in Madrid, results of a VHIO prospective study point to the promise of…
Developed by VHIO investigators, VIGex is a gene expression signature that classifies solid tumors into three categories based on the…
Recently published open access in the journal Nature Communications*, an invited Comment article first authored by VHIO’s Elena Garralda, sets…
